An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Trial Profile

An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Acronyms ASPIRE
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 04 Aug 2017 This trial has been completed in Spain, according to European Clinical Trials Database
    • 28 Jul 2017 Planned primary completion date changed from 14 Jul 2017 to 1 Aug 2017.
    • 06 Jul 2017 According to a Bioverativ media release, updated analyses of long-term follow-up data from this trial will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top